Allogeneic Stem Cell Transplant Feasible for Leukemia in Elderly Patients
TUESDAY, Feb. 21, 2023 -- In elderly adults aged 60 years and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplant (HSCT) can be performed with acceptable overall survival and...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants